Avenue Therapeutics, Inc. Profile Avatar - Palmy Investing

Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in…

Biotechnology
US, New York [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Avenue Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ATXI's Analysis
CIK: 1644963 CUSIP: 05360L205 ISIN: US05360L3042 LEI: - UEI: -
Secondary Listings
ATXI has no secondary listings inside our databases.